Effectiveness of short-term olanzapine in patients with bipolar i disorder, with or without comorbidity with substance use disorder

Journal of Clinical Psychopharmacology

Volumn 33, Issue 2, 2013, Pages 231-235

  Sani, Gabriele ^a,b   Kotzalidis, Georgios D ^a,c   Vöhringer, Paul ^d,e   Pucci, Daniela ^a   Simonetti, Alessio ^a,b   Manfredi, Giovanni ^a,b   Savoja, Valeria ^a,e   Tamorri, Stefano Maria ^a,e   Mazzarini, Lorenzo ^a,c,g   Pacchiarotti, Isabella ^a,c   Telesforo, Carla Ludovica ^a   Ferracuti, Stefano ^a   Brugnoli, Roberto ^a   Ambrosi, Elisa ^a   Caloro, Matteo ^a,f   Del Casale, Antonio ^a,b   Koukopoulos, Alexia E ^a,b   Vergne, Derick E ^d   Girardi, Paolo ^a,b,g   Nassir Ghaemi, S ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Centro Lucio Bini   (Italy)

^c UNIVERSITY OF BARCELONA   (Spain)

^d TUFTS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CHILE   (Chile)

^f IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^g Villa Rosa   (Italy)

Author keywords

bipolar disorder type I; comorbidity; craving; olanzapine; substance use disorder

Indexed keywords

GLUCOSE; OLANZAPINE;

ADULT; ARTICLE; BIPOLAR I DISORDER; BODY MASS; COMORBIDITY; DEPRESSION; DRUG ABUSE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL PATIENT; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; SHORT COURSE THERAPY; SUBSTANCE ABUSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874935355     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318287019c     Document Type: Article

References (43)

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518.
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19. (Pubitemid 24028993)
3. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627. (Pubitemid 40973437)
4. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:807-816. (Pubitemid 39031120)
5. Brady KT, Sonne SC. The relationship between substance abuse and bipolar disorder. J Clin Psychiatry. 1995;56(suppl 3):19-24.
6. Brady KT, Sonne SC, Anton R, et al. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995;56:118-121.
7. Sonne SC, Brady KT. Valproate for alcoholics with bipolar disorder. Am J Psychiatry. 1999;156:1122.
8. Salloum IM, Cornelius JR, Daley DC, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62:37-45. (Pubitemid 40096069)
9. Brady KT, Sonne SC, Malcolm RJ, et al. Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder. Exp Clin Psychopharmacol. 2002;10:276-285. (Pubitemid 34919936)
10. Brown ES, Nejtek VA, Perantie DC, et al. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry. 2003;64:197-201. (Pubitemid 36268323)
11. Brown ES, Perantie DC, Dhanani N, et al. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. J Affect Disord. 2006;93:219-222. (Pubitemid 43816049)
12. Rubio G, López-Muñoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord. 2006;8:289-293.
13. Nunes EV, McGrath PJ, Wager S, et al. Lithium treatment for cocaine abusers with bipolar spectrum disorder. Am J Psychiatry. 1990;147:655-657. (Pubitemid 20153443)
14. Geller B, Cooper TB, Sun K, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry. 1998;37:171-178. (Pubitemid 28099184)
15. Brown ES, Nejtek VA, Perantie DC, et al. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord. 2002;4:406-411. (Pubitemid 36041471)
16. Longoria J, Brown ES, Perantie DC, et al. Quetiapine for alcohol use and craving in bipolar disorder. J Clin Psychopharmacol. 2004;24:101-102. (Pubitemid 38134178)
17. Brown ES, Jeffress J, Liggin JD, et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry. 2005;66:756-760. (Pubitemid 40942423)
18. Anton RF, Kranzler H, Breder C, et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28:5-12.
19. Vergne DE, Anton RF. Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS Neurol Disord Drug Targets. 2010;9:50-54.
20. Littrell KH, Petty RG, Hilligoss NM, et al. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treatment. 2001;21:217-221. (Pubitemid 34041006)
21. Tsuang J, Marder SR, Han A, et al. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry. 2002;63:1180-1181. (Pubitemid 36084066)
22. Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance abusing individuals with schizophrenia. Am J Addict. 2007;16:260-268. (Pubitemid 47174581)
23. Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol. 2006;26:9-12. (Pubitemid 43167083)
24. Gerra G, Di Petta G, D'Amore A, et al. Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clin Neuropharmacol. 2007;30:127-135. (Pubitemid 46871862)
25. Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 2005;193:379-386. (Pubitemid 40800627)
26. Sattar SP, Grant K, Bhatia S, et al. Potential use of olanzapine in treatment of substance dependence disorders. J Clin Psychopharmacol. 2003;23:413-415. (Pubitemid 36951186)
27. Sattar SP, Bhatia SC. Olanzapine for cocaine cravings and relapse prevention. J Clin Psychiatry. 2003;64:969. (Pubitemid 37022767)
28. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435. (Pubitemid 9006756)
29. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
30. Overall JE. Psychological measurements in psychopharmacology. Mod Probl Pharmacopsychiat. 1974;7:67-78.
31. Maxwell C. Sensitivity and accuracy with the visual analogue scale: a psycho-physical classroom experiment. Br J Clin Pharmacol. 1978;6:15-24. (Pubitemid 8364021)
32. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen JP, eds. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Totowa, NJ: Humana Press; 1992:41-72.
33. Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res. 1998;33:95-101. (Pubitemid 28439250)
34. van Nimwegen LJ, de Haan L, van Beveren NJ, et al. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Can J Psychiatry. 2008;53:400-405. (Pubitemid 351878642)
35. Hutchison KE, Rutter MC, Niaura R, et al. Olanzapine attenuates cue-elicited craving for tobacco. Psychopharmacology (Berl). 2004;175:407-413. (Pubitemid 39362038)
36. Hutchison KE, Ray L, Sandman E, et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006;31:1310-1317. (Pubitemid 43971847)
37. Hamilton JD, Nguyen QX, Gerber RM, et al. Olanzapine in cocaine dependence: a double-blind, placebo-controlled trial. Am J Addict. 2009;18:48-52.
38. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 2003;70:265-273. (Pubitemid 36577338)
39. Ninan I, Kulkarni SK. Differential effects of olanzapine at dopamine D1 and D2 receptors in dopamine depleted animals. Psychopharmacology (Berl). 1999;142:175-181. (Pubitemid 29190853)
40. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther. 1999;288:774-781. (Pubitemid 29119694)
41. Li XM, Perry KW, Wong DT, et al. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl). 1998;136:153-161. (Pubitemid 28137955)
42. Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl). 1999;141:267-278. (Pubitemid 29196076)
43. Hutchison KE, Wooden A, Swift RM, et al. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology. 2003;28:1882-1888. (Pubitemid 41070854)